# iiShield

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iishield

- Headquarters: Sydney, Australia
- Website: www.iishield.com
- Total disclosed funding: $1M
- Latest round: Seed (Oct 23, 2025)
- Investors on record: 2

## About

Based in Australia, iiShield is a medical device company specializing in advanced protective solutions for vital organs, focusing on innovative gear that reduces risks associated with physical impacts across various sectors.iiShield, founded in 2020 and headquartered in Sydney, Australia, develops protective gear designed for vital organs. The company secured USD 1.00 mn in Seed funding from Sydney Angels and VentureCrowd in October 2025. With a total of 1 deal to date, iiShield aims to enhance user safety through targeted protective solutions.iiShield specializes in advanced protective solutions designed specifically for vital organs. The company’s core offerings focus on innovative protective gear that mitigates risks associated with physical impacts, making them suitable for various applications, including sports, military, and healthcare sectors. These products are engineered using cutting-edge materials that combine durability and flexibility, providing users with optimal protection without compromising comfort or mobility. The company targets a diverse clientele that includes athletes, military personnel, and medical professionals across multiple geographical markets, including North America, Europe, and parts of Asia. Each product is tailored to address the unique challenges faced by its users, aiming to enhance safety and performance in high-risk environments.The revenue model for iiShield is structured around direct-to-consumer sales, B2B partnerships, and collaborations with retailers and wholesalers. The company engages in business transactions primarily through the sale of its flagship protective products, which cater to a wide range of consumer needs. Pricing plans are established based on the specific requirements and volume of purchases, ensuring competitive rates for both individual consumers and bulk buyers. For instance, bulk orders from organizations such as sports teams or military units would likely involve negotiated contracts to secure favorable pricing. The combination of direct sales and partnerships allows iiShield to maintain a robust revenue stream while ensuring its products remain accessible to a broad customer base.In October 2025, iiShield raised USD 1.00 mn in Seed funding, which will be utilized to conduct clinical trials for its kidney protective device and to prepare for a global market entry. The company plans to expand its product line, focusing on launching new protective solutions in the healthcare sector by late 2026, targeting markets in Europe and Asia as part of its growth strategy.

## Funding rounds

- Seed, Oct 23, 2025, $1M — Artesian, VentureCrowd

## Investors

- Artesian (https://capitalatlas.ai/funds/artesian) — Seed
- VentureCrowd — Seed